Zhejiang Tianyu Pharmaceutical Co Ltd (SHE:300702) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Tianyu Pharmaceutical Co Ltd (300702)
Zhejiang Tianyu Pharmaceutical Co Ltd (SHE:300702) has a market capitalization of $1.07 Billion (CN¥7.34 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #8796 globally and #2320 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Tianyu Pharmaceutical Co Ltd's stock price CN¥21.09 by its total outstanding shares 347977159 (347.98 Million). Analyse cash flow conversion of Zhejiang Tianyu Pharmaceutical Co Ltd to see how efficiently the company converts income to cash.
Zhejiang Tianyu Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Zhejiang Tianyu Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $760.42 Million to $1.07 Billion (7.05% CAGR).
Zhejiang Tianyu Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Tianyu Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.32x
Zhejiang Tianyu Pharmaceutical Co Ltd's market cap is 0.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.17x
Zhejiang Tianyu Pharmaceutical Co Ltd's market cap is 15.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $760.42 Million | $1.19 Billion | $100.18 Million | 0.64x | 7.59x |
| 2018 | $605.10 Million | $1.47 Billion | $163.66 Million | 0.41x | 3.70x |
| 2019 | $1.39 Billion | $2.11 Billion | $585.73 Million | 0.66x | 2.38x |
| 2020 | $2.61 Billion | $2.59 Billion | $667.06 Million | 1.01x | 3.92x |
| 2021 | $2.45 Billion | $2.55 Billion | $204.68 Million | 0.96x | 11.96x |
| 2022 | $1.30 Billion | $2.67 Billion | -$118.87 Million | 0.49x | N/A |
| 2023 | $1.10 Billion | $2.53 Billion | $27.36 Million | 0.44x | 40.30x |
| 2024 | $848.33 Million | $2.63 Billion | $55.94 Million | 0.32x | 15.17x |
Competitor Companies of 300702 by Market Capitalization
Companies near Zhejiang Tianyu Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Zhejiang Tianyu Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Zhejiang Tianyu Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Tianyu Pharmaceutical Co Ltd's market cap moved from $760.42 Million to $ 1.07 Billion, with a yearly change of 7.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.07 Billion | -10.64% |
| 2025 | CN¥1.20 Billion | +41.66% |
| 2024 | CN¥848.33 Million | -23.06% |
| 2023 | CN¥1.10 Billion | -14.93% |
| 2022 | CN¥1.30 Billion | -47.07% |
| 2021 | CN¥2.45 Billion | -6.24% |
| 2020 | CN¥2.61 Billion | +87.37% |
| 2019 | CN¥1.39 Billion | +130.36% |
| 2018 | CN¥605.10 Million | -20.43% |
| 2017 | CN¥760.42 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Zhejiang Tianyu Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.07 Billion USD |
| MoneyControl | $1.07 Billion USD |
| MarketWatch | $1.07 Billion USD |
| marketcap.company | $1.07 Billion USD |
| Reuters | $1.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical … Read more